Evidence map›Paper›PMID 42681672›Full record

ReviewBiomarker research2026

Cancer of unknown primary: the evolution of tissue of origin identification in the artificial intelligence era.

Xinyue Zeng, I Weng Lao, Yifeng Sun, Qifeng Wang, Xiaowei Zhang, Zhiguo Luo, Xiaoyan Zhou, Midie Xu

Abstract readReview
In one paragraph

Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinyue Zeng *Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
I Weng Lao *Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yifeng SunDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Qifeng WangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xiaowei ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Zhiguo LuoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Xiaoyan ZhouDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Midie XuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. 12111230022@fudan.edu.cn.

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-Young2023-0023Innovation Program of Shanghai Science and Technology Committee 20Z11900300National Natural Science Foundation of China 82272626National Natural Science Foundation of China 82573699Shanghai Clinical Research Project of Shanghai Shenkang Hospital Development Center SHDC2020CR4068
6 · The paper itself

Abstract

Cancer of Unknown Primary (CUP) presents substantial diagnostic and therapeutic challenges owing to its heterogeneous nature and the absence of an identifiable primary tumor site. This review provides a structured search of the pathogenesis, epidemiological characteristics, and limitations of traditional diagnostic and therapeutic approaches for CUP, with an emphasis on the evolution of Tissue of Origin (TOO) identification techniques. Recent advances in precision medicine have accelerated the development of machine learning-based TOO identification tools, representing a paradigm shift in CUP diagnostics. Deep learning (DL) algorithms that integrate multi-omics data (such as genomics and transcriptomics) with clinical features have markedly enhanced the accuracy of tracing tumor origin, and artificial intelligence (AI) driven TOO models are increasingly being incorporated into clinical practice, offering new insights for pathological diagnosis, treatment selection, and prognostic evaluation. Nevertheless, several challenges remain, including issues of data standardization, model generalizability, and interpretability. Ethical considerations related to data privacy, algorithmic fairness, and clinical implementation also warrant careful attention. Future research should focus on establishing standardized multi-center databases, developing more interpretable AI models, and fostering multidisciplinary collaborative strategies for CUP management. Through continued refinement of technical solutions and regulatory guidelines, TOO identification is anticipated to progress from research to routine clinical application, ultimately supporting precise and personalized care for patients with CUP.

Indexed as

Artificial intelligenceCancer of unknown primaryMultimodal omicsPrecision oncologyTissue of origin

Identifiers

PMID42681672
PMCPMC13536826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.